Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00017602 · ClinicalTrials.gov registry record · Phase 3
Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 3 study of Multiple Myeloma and Plasma Cell Neoplasm, sponsored by Genta Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 1
- Study location
NCT00017602 is a Phase 3 study of Multiple Myeloma and Plasma Cell Neoplasm that has completed, run by Genta Incorporated. The trial reports 1 study location across 1 state.
The verdict
NCT00017602, a Phase 3 study of Multiple Myeloma and Plasma Cell Neoplasm, has completed, sponsored by Genta Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of dexamethasone by making cancer cells more sensitive to the drug. It is not yet known if dexamethasone is more effective with or without oblimersen in treating multiple myeloma. PURPOSE: Randomized phase III trial to compare the effectiveness of dexamethasone with or without oblimersen in treating patients who have relapsed or refractory multiple myeloma.
Conditions Studied
Interventions
- DRUG dexamethasone
- BIOLOGICAL oblimersen sodium
Study Locations (1)
New Jersey
- Genta Incorporated - Berkeley Heights
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-12 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00017602
The ClinicalTrials.gov registry entry for NCT00017602 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Genta Incorporated, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma and Plasma Cell Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which dexamethasone is the first listed.
NCT00017602 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT00017602 about?
NCT00017602 is a clinical study titled "Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of dexamethasone by making cancer cells more sensitive to the drug. It is not yet known if dexamethasone is more effective with or withou...
What is the current status of trial NCT00017602?
This trial is currently completed. It is a Phase 3 study. The study started on 2000-12. Estimated completion is 2009-04.
What conditions does trial NCT00017602 study?
This clinical trial studies the following conditions: Multiple Myeloma and Plasma Cell Neoplasm.
What interventions are being tested in trial NCT00017602?
The interventions under investigation include: dexamethasone (DRUG), oblimersen sodium (BIOLOGICAL).
Who is sponsoring clinical trial NCT00017602?
This trial is sponsored by Genta Incorporated, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00017602 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma and Plasma Cell Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED · Phase 3
-
Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma
COMPLETED · Phase 3
-
Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
COMPLETED · Phase 3
-
Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain
COMPLETED · Phase 3
-
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
COMPLETED · Phase 3
-
Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.